text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 41859-67-0 | Product Number: B3346

Bezafibrate


Purity: >98.0%(T)(HPLC)
Synonyms:
  • 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid
Documents:
5G
£69.00
1   ≥20 
25G
£160.00
3   ≥20 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number B3346
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__1__9H__2__0ClNO__4 = 361.82  
Physical State (20 deg.C) Solid
CAS RN 41859-67-0
Reaxys Registry Number 4267656
PubChem Substance ID 87560846
Merck Index (14) 1195
MDL Number

MFCD00078970

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 98.0 %
Melting point 182.0 to 186.0 °C
Properties (reference)
Melting Point 184 °C
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H302 : Harmful if swallowed.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P270 : Do not eat, drink or smoke when using this product.
P264 : Wash skin thoroughly after handling.
P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
Related Laws:
EC Number 255-567-9
RTECS# UE8755000
Transport Information:
HS Number 2924297099
Application
Bezafibrate: Antilipemic with Activity against Peroxisome Proliferator-Activated Receptors (PPARs)

The fibrates, including bezafibrate, clofibrate [C0941], clinofibrate [C3100] and fenofibrate [F0674] are lower elevated serum lipids by decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fibrates increase the high density lipoprotein (HDL) cholesterol fraction. The precise mechanisms of action remain unknown, but it has been reported that the major modes of action of the fibrates as follows: VLDL catabolism by increased lipoprotein and hepatic triglyceride lipase activities; suppression of triglyceride biosynthesis by acetyl-CoA carboxylase enzyme inhibition and attenuation of cholesterol biosynthesis by inhibition of the rate-limiting HMG-CoA reductase.
Since the late 1990s, it has been reported that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs) which activation increases HDL cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. (The product is for research purpose only.)

References


PubMed Literature


Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents